SARS-CoV-2 Antigen Rapid Test for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
American Research Labs, Lake Worth, FL
COVID-19+1 More
Sky Medical™ Rapid Antigen Test - DiagnosticTest
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

Prospective study that will evaluate the clinical agreement of the Sky Medical™ Rapid Antigen Test compared to SARS-CoV-2 RT-PCR.

Eligible Conditions

  • Sars-CoV-2 Infection
  • COVID-19

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 90 Days

90 Days
Percent Positive Agreement and Negative Percent Agreement

Trial Safety

Trial Design

1 Treatment Group

SARS-CoV-2 Antigen Rapid Test
1 of 1
Experimental Treatment

200 Total Participants · 1 Treatment Group

Primary Treatment: SARS-CoV-2 Antigen Rapid Test · No Placebo Group · N/A

SARS-CoV-2 Antigen Rapid Test
DiagnosticTest
Experimental Group · 1 Intervention: Sky Medical™ Rapid Antigen Test · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days
Closest Location: American Research Labs · Lake Worth, FL
N/AFirst Recorded Clinical Trial
1 TrialsResearching COVID-19
0 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subject is appropriate for nasopharyngeal sample collection.
You are willing to provide nasopharyngeal samples.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.